Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Trial Profile

A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motixafortide (Primary)
  • Indications Stem cell mobilisation
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 23 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2018 Results evaluating the safety and efficacy of BL-8040 for the mobilization of donor haematopoietic stem and progenitor cells for allogeneic hematopoietic cell transplantation and phenotypic characterization of the leukapheresis product presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Nov 2018 Planned End Date changed from 30 Dec 2023 to 12 Apr 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top